Advertisement

Burden of comorbidities in South Africans with systemic lupus erythematosus

  • L. Greenstein
  • K. Makan
  • Mohammed TiklyEmail author
Original Article
  • 24 Downloads

Abstract

Introduction

To investigate the prevalence and spectrum of comorbidities in South Africans with systemic lupus erythematosus (SLE).

Patients and methods

A nested case-control study of a known alive group (AG) and deceased group (DG) of 200 and 40 patients, respectively, matched for age and sex, attending a tertiary Lupus Clinic. Comorbidities that were documented included, but not restricted to, those listed in the Charlson comorbidity index (CCI). Lupus disease severity was assessed using the lupus severity index (LSI).

Results

Patients were mainly black female (94%), and the median age (IQR) and median disease duration (IQR) were 33 (25–42) and 6 (3–11) years, respectively. Overall, 191 (79.5%) patients experienced ≥ 1 comorbidities. The median (IQR) LSI and CCI scores were significantly higher in the DG than the AG (8.5 (6.7–9.1) vs 6.3 (5.2–8.3), p < 0.001 and 1 (1–3) vs 0 (0–2), p = 0.002, respectively). The commonest comorbidities were hypertension (42%), serious infections (36.6%) and tuberculosis (TB) (18.8%), the latter two being significantly more common in the DG (OR = 7.34, p < 0.0001 and OR = 3.40, p = 0.001, respectively). Of the CCI comorbidities, congestive cardiac failure (OR = 10.39, p = 0.0003), cerebrovascular disease (OR = 7.29, p = 0.01) and chronic kidney disease (OR = 3.08, p = 0.02) were more common in the DG. Both serious infections and TB were independent predictors of death.

Conclusion

In this study of predominantly black South African SLE patients, comorbidities were common, with serious infections and TB amongst the commonest comorbidities. Unlike in industrialised Caucasian populations, cardiovascular comorbidities were rare in spite of a high prevalence of HPT.

Keywords

Africa Comorbidities Infections SLE Tuberculosis 

Notes

Funding information

This work has been supported by the Connective Tissue Diseases Research Fund, University of the Witwatersrand, and Medical Research Council of South Africa.

Compliance with ethical standards

Ethical standards

The study was approved by the Human Research Ethics Committee of the University of the Witwatersrand (clearance certificate number M1409790), and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Disclosure

None.

References

  1. 1.
    Tikly M, Navarra SV (2008) Lupus in the developing world--is it any different? Best Pract Res Clin Rheumatol 22(4):643–655Google Scholar
  2. 2.
    Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 56(11):1945–1961CrossRefGoogle Scholar
  3. 3.
    Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60(2):221–225CrossRefGoogle Scholar
  4. 4.
    Wadee S, Tikly M, Hopley M (2007) Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology 46(9):1487–1491CrossRefGoogle Scholar
  5. 5.
    Dubula T, Mody GM (2015) Spectrum of infections and outcome among hospitalized South Africans with systemic lupus erythematosus. Clin Rheumatol 34(3):479–488CrossRefGoogle Scholar
  6. 6.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Goral A, de Ramon E, Fernandez-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GR (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European working party on systemic lupus erythematosus. Medicine 78(3):167–175CrossRefGoogle Scholar
  7. 7.
    Kang SC, Hwang SJ, Chang YS, Chou CT, Tsai CY (2012) Characteristics of comorbidities and costs among patients who died from systemic lupus erythematosus in Taiwan. Arch Med Sci : AMS 8 (4):690–696Google Scholar
  8. 8.
    Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE (2015) Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 27(5):454–460CrossRefGoogle Scholar
  9. 9.
    Wolfe F, Michaud K, Li T, Katz RS (2010) Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 37(2):305–315CrossRefGoogle Scholar
  10. 10.
    Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, Calvo-Alen J, Del Campo V, Olive-Marques A, Perez-Vicente S, Fernandez-Nebro A, Andres M, Erausquin C, Tomero E, Horcada L, Uriarte E, Freire M, Montilla C, Sanchez-Atrio A, Santos G, Boteanu A, Diez-Alvarez E, Narvaez J, Martinez-Taboada V, Silva-Fernandez L, Ruiz-Lucea E, Andreu JL, Hernandez-Beriain JA, Gantes M, Hernandez-Cruz B, Perez-Venegas J, Pecondon-Espanol A, Marras C, Ibanez-Barcelo M, Bonilla G, Torrente V, Castellvi I, Alegre JJ, Calvet J, Marenco JL, Raya E, Vazquez T, Quevedo V, Munoz-Fernandez S, Rodriguez-Gomez M, Ibanez J, Pego-Reigosa JM (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47(1):38–45CrossRefGoogle Scholar
  11. 11.
    Barnado A, Carroll RJ, Casey C, Wheless L, Denny JC, Crofford LJ (2018) Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus. Arthritis Res Therapy 20(1):69CrossRefGoogle Scholar
  12. 12.
    Barbhaiya M, Feldman CH, Guan H, Gomez-Puerta JA, Fischer MA, Solomon DH, Everett B, Costenbader KH (2017) Race/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheum (Hoboken, NJ) 69(9):1823–1831CrossRefGoogle Scholar
  13. 13.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefGoogle Scholar
  14. 14.
    Jonsen A, Clarke AE, Joseph L, Belisle P, Bernatsky S, Nived O, Bengtsson AA, Sturfelt G, Pineau CA (2011) Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res 63(9):1233–1237CrossRefGoogle Scholar
  15. 15.
    Bello GA, Brown MA, Kelly JA, Thanou A, James JA, Montgomery CG (2016) Development and validation of a simple lupus severity index using ACR criteria for classification of SLE. Lupus Sci Med 3(1):e000136CrossRefGoogle Scholar
  16. 16.
    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15(2):241–250CrossRefGoogle Scholar
  17. 17.
    Hodkinson B, Musenge E, Tikly M (2009) Osteoarticular tuberculosis in patients with systemic lupus erythematosus. QJM : Monthly J Assoc Phys 102(5):321–328CrossRefGoogle Scholar
  18. 18.
    World Health Organisiation (2017) Global Health Education information about tuberculosis. Switzerland, Geneva Accessed 12 January 2017Google Scholar
  19. 19.
    Oloo SA (2016) Implications of the 2015 World Health Organization isoniazid preventive therapy recommendations on tuberculosis prevention efforts in Namibia. South Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde 106(8):775–776Google Scholar
  20. 20.
    Falagas ME, Voidonikola PT, Angelousi AG (2007) Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 30(6):477–486CrossRefGoogle Scholar
  21. 21.
    Mok MY, Lo Y, Chan TM, Wong WS, Lau CS (2005) Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 32(4):609–615Google Scholar
  22. 22.
    Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR (2002) Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61(3):251–253CrossRefGoogle Scholar
  23. 23.
    Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcon GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB (2015) Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 74(9):1706–1713CrossRefGoogle Scholar
  24. 24.
    Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S (2008) Spectrum of heart disease and risk factors in a black urban population in South Africa (the heart of Soweto study): a cohort study. Lancet (London, England) 371(9616):915–922CrossRefGoogle Scholar
  25. 25.
    Thorburn CM, Ward MM (2003) Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum 48(9):2519–2523CrossRefGoogle Scholar
  26. 26.
    Tallbacka KR, Pettersson T, Pukkala E (2018) Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. Scand J Rheumatol:1–4Google Scholar
  27. 27.
    Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ (2004) Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 31(9):1763–1767Google Scholar
  28. 28.
    Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52(11):3651–3659CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineChris Hani Baragwanath Academic Hospital, University of the WitwatersrandJohannesburgSouth Africa
  2. 2.Division of RheumatologyChris Hani Baragwanath Academic Hospital and University of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations